Journal Article

Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells

Silkenstedt Elisabeth, Aymerich, Marta, Fuentes, Patricia, García-León, María J, Giró Ariadna, López-Guillermo, Armando, Colomer Dolors, Lee-Vergés Eriong, Rosich Laia, Xargay-Torrent Sílvia, Roldán Jocabed, Puente Xose S, González-Farré Blanca, Campo, Elias, Villamor Neus, Delgado, Julio, López-Guerra Mónica, Giménez Neus, Toribio, María L

2020

Overview

Targeting Notch signaling has emerged as a promising therapeutic strategy for chronic lymphocytic leukemia (CLL), particularly in NOTCH1-mutated patients. We provide first evidence that the Notch ligand DLL4 is a potent stimulator of Notch signaling in NOTCH1-mutated CLL cells while increases cell proliferation. Importantly, DLL4 is expressed in histiocytes from the lymph node, both in NOTCH1-mutated and -unmutated cases. We also show that the DLL4-induced activation of the Notch signaling pathway can be efficiently blocked with the specific anti-Notch1 antibody OMP-52M51. Accordingly, OMP-52M51 also reverses Notch-induced MYC, CCND1, and NPM1 gene expression as well as cell proliferation in NOTCH1-mutated CLL cells. In addition, DLL4 stimulation triggers the expression of protumor target genes, such as CXCR4, NRARP, and VEGFA, together with an increase in cell migration and angiogenesis. All these events can be antagonized by OMP-52M51. Collectively, our results emphasize the role of DLL4 stimulation in NOTCH1-mutated CLL and confirm the specific therapeutic targeting of Notch1 as a promising approach for this group of poor prognosis CLL patients.

• Publisher: Nature Publishing Group
• Subject: Angiogenesis / Cell adhesion & migration / Cell growth / Cell migration / Cell proliferation / Chronic lymphocytic leukemia / CXCR4 protein / Gene expression / Lymph nodes / Lymphatic leukemia / Myc protein / Notch1 protein / Outer membrane proteins / Signal transduction / Therapeutic targets